BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

费城和不列颠哥伦比亚省温哥华讯 - 专注于癌症免疫疗法的临床阶段生物技术公司BriaCell Therapeutics Corp.今日宣布计划进行普通股的尽力公开发售。该公司目前市值为250万美元，EBITDA为-422万美元，正积极寻求加强其财务状况。此次发售的完成和具体条款将取决于市场条件，目前尚无法确定发售是否能够完成及其具体细节。

周二，H.C. Wainwright分析师Emily Bodnar将Briacell Therapeutics (NASDAQ: BCTX ...

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has ...

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...

H.C. Wainwright analyst Emily Bodnar increased the price target for Briacell Therapeutics (NASDAQ:BCTX) to $32 from the previous $15, while maintaining a Buy rating on the stock. The company, ...

BriaCell Therapeutics (TSX:BCT) is reporting that the first metastatic breast cancer patient treated with its Bria-OTS ...

Therapeutics announces an unprecedented clinical response including resolution of a lung metastasis with stable disease ...

Shares of BriaCell Therapeutics were trading at all-time lows in Monday's after-hours market, following news the company plans to sell shares in a best-efforts public offering.